Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets open firm
Tue, 29 Mar 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets Japan (down 1.3%) and Indonesia (down 0.7%) trading in the red. However, stocks markets in China (up 0.2%) and Taiwan (up o.1%) are trading firm. Indian stock markets have opened the day on a firm note. Stocks from auto and consumer durable space are leading the gains. However, stocks from the realty and healthcare space are trading weak.

The BSE-Sensex is trading higher by around 44 points (0.2%), while the NSE-Nifty is up by around 12 points (0.2%). Mid and small cap stocks are also trading firm, with both the BSE Midcap index and BSE Small cap index up by 0.3% and 0.2% respectively. The rupee is trading at 44.79 to the US dollar.

Steel stocks have opened the day on a weak note with SAIL, Tata Steel, Jindal Steel and Bhushan Steel trading in the red. Steel major Tata Steel has devised a novel way to produce iron-ore from waste. The technology is similar to a patented technology of Japan’s Kobe Steel used for the production of iron ore nuggets. The process has been tested by Tata Steel at its research and development centre. Currently, the company dumps its waste in a vast storage pond. However, it may soon run out of storage space. The new process will allow that waste material to be commercially used during the process of iron ore beneficiation. This will help cut steelmaking costs.

The company plans to build a pilot plant in Jamshedpur to test the technology commercially. It is deliberating with the central government for the same.

Pharma stocks have also opened the day on a weak note with Apollo Hospital, Sun Pharma, Ranbaxy Lab and Jubilant Life trading in the red. Dr Reddy's Lab, the Indian pharma company, has launched Levocetirizine tablets in the US market. The drug, which is the generic version of UCB Inc's Xyzal tablets, is used to treat or prevent symptoms of allergies. It is also used to help reduce itchy skin rash and hives. The US Food and Drug Administration (FDA) approved its abbreviated new drug application for levocetirizine tablets on February 24. The company has launched the tablet in 5 mg strength in the US market. According IMS Health Sales data, levocetirizine tablets posted sales of about US$ 238 m in the US market for the 12-month period ended September 30, 2010.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.